Get the Stockscreener App
6.60
0.00%
0.00
Trevi Therapeutics Inc stock is traded at $6.60, with a volume of 1.43M.
It is up +0.00% in the last 24 hours and up +22.22% over the past month.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$6.60
Open:
$7.13
24h Volume:
1.43M
Relative Volume:
0.65
Market Cap:
$675.81M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-22.76
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
-5.58%
1M Performance:
+22.22%
6M Performance:
+126.80%
1Y Performance:
+126.03%
1-Day Range:
$6.37
$7.1687
1-Week Range:
$6.37
$7.1687
52-Week Range:
$2.30
$7.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Name
Trevi Therapeutics Inc
Sector
Industry
Phone
203-304-2499
Address
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
6.60 | 675.81M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-25 | Reiterated | Needham | Buy |
| Mar-10-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Dec-12-24 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-30-24 | Initiated | Raymond James | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-12-23 | Initiated | B. Riley Securities | Buy |
| Nov-22-22 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | BMO Capital Markets | Outperform |
| Jun-03-19 | Initiated | Needham | Buy |
| Jun-03-19 | Initiated | SVB Leerink | Outperform |
| Jun-03-19 | Initiated | Stifel | Buy |
View All
Trevi Therapeutics Inc Stock (TRVI) Latest News
Trevi Therapeutics Reports Q1 2025 Results and Updates - TipRanks
MetLife Investment Management LLC Purchases 19,857 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance
Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations By Investing.com - Investing.com UK
Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations - Investing.com
Trevi Therapeutics (TRVI): Promising Data and Strategic Advances - GuruFocus
Trevi Therapeutics (TRVI): Promising Data and Strategic Advances | TRVI Stock News - GuruFocus
Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings: EPS of -$0.09 Beats Estimate, Reports $10.3 Million Net Loss - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | TRVI Stock News - GuruFocus
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan
Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts - Defense World
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Invesco Ltd. Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Renaissance Technologies LLC Acquires 29,700 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - Defense World
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 - StreetInsider
Trevi Therapeutics to Report First Quarter 2025 Financial Result - GuruFocus
Trevi Therapeutics Inc [TRVI] Records 50-Day SMA of $5.77 - knoxdaily.com
Indo-Asian News Service - Indo-Asian News Service (IANS)
A look at TRVI’s current quarter earnings estimates - uspostnews.com
TRVI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Quarterly Metrics: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX
SEC Form DEF 14A filed by Trevi Therapeutics Inc. - Quantisnow
JPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Recent Insider Activity Suggests Potential Gains for Trevi Therapeutics Inc (TRVI) - knoxdaily.com
What is Trevi Therapeutics Inc (TRVI) Stock Return on Shareholders’ Capital? - Sete News
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Has $5.35 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Quarterly Snapshot: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics Inc (TRVI)’s results reveal risk - uspostnews.com
Stifel maintains Trevi Therapeutics stock Buy rating, $15 target By Investing.com - Investing.com Canada
12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Raymond James Financial Inc. - Defense World
American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of “Buy” by Analysts - Defense World
Trevi Therapeutics Sees Unusually Large Options Volume (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at Needham & Company LLC - Defense World
Trevi Therapeutics at 24th Annual Needham: Strategic Advances in Cough Treatments - Investing.com Canada
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha
Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail
Trevi Therapeutics to Participate in Upcoming April Investor Conferences - The Malaysian Reserve
Trevi's Game-Changing Chronic Cough Treatment Takes Center Stage at 3 Major Healthcare Conferences - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short Interest - Defense World
Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
What to expect from TRVI’s earnings report this quarter? - uspostnews.com
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news
Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones | NASDAQ:TRVI - Proactive Investors
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock By Investing.com - Investing.com Australia
Trevi Therapeutics Inc Stock (TRVI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Trevi Therapeutics Inc Stock (TRVI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SCIASCIA THOMAS | Chief Scientific Officer |
Mar 25 '25 |
Sale |
6.60 |
2,631 |
17,365 |
221,373 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Option Exercise |
1.43 |
5,263 |
7,526 |
218,576 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Sale |
6.58 |
5,263 |
34,625 |
213,313 |
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):